文献速递眼底病与葡萄膜炎眼整形与眼眶

质子束照射后经内路肿瘤辅助治疗

Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation.
PubMed 文献 · Am J Ophthalmol · 2017-03-30

该回顾性队列研究纳入1998年6月至2015年6月因脉络膜或睫状体黑色素瘤接受初次质子束治疗的2499例患者,5年局部肿瘤控制率95.9%、保眼率94.8%,110例(4.4%)需二次眼球摘除。内路切除组5年免眼球摘除生存率94.8%,内路引流组94.3%,对照组93.5%。作者认为较大肿瘤中辅助手术可能降低眼球摘除与新生血管性青光眼发生率,内路引流-玻璃体切除术推荐用于不适合内路切除者。

要点

  • 2499例质子束治疗后5年局部控制率95.9%、保眼率94.8%,二次眼球摘除110例(4.4%)。
  • 难治性新生血管性青光眼是二次眼球摘除首要原因,占2499例中的78例(3.1%)。
  • 内路切除组5年免眼球摘除生存率94.8%,对照组比较log-rank检验P=.014。

核心结论

  • 该研究表明,在较大肿瘤中辅助手术可能降低眼球摘除率和新生血管性青光眼发生率。
  • 内路切除是最有前景的辅助治疗选择,但作者推荐对不适合内路切除的患者行内路引流-玻璃体切除术。

研究设计与样本

  • 回顾性队列研究,纳入1998年6月至2015年6月因脉络膜或睫状体黑色素瘤接受初次质子束治疗的全部患者。
  • 共2499例患者接受初次质子束治疗。

主要发现

  • 5年局部肿瘤控制率为95.9%,5年保眼率为94.8%。
  • 110例(4.4%)需二次眼球摘除,其中难治性新生血管性青光眼为二次眼球摘除的首要原因,占2499例中的78例(3.1%)。
  • 5年免眼球摘除生存率:内路切除组94.8%,内路引流组94.3%,对照组93.5%;log-rank检验对照组对内路切除组P=.014,对照组对内路引流-玻璃体切除术组P=.06。
  • 5年放射性视网膜病变发生率:内路切除组30.5%、内路引流-玻璃体切除术组37.4%,对照组52.3%;Kaplan-Meier检验P=.001与P=.048。
  • 5年新生血管性青光眼发生率:内路切除组11.6%、内路引流-玻璃体切除术组21.3%,对照组57.8%;Kaplan-Meier检验P=.001与P=.01。

关键数值与推荐

  • 5年局部肿瘤控制率95.9%,5年保眼率94.8%(2499例初次质子束治疗患者)。
  • 二次眼球摘除110例(4.4%),其中难治性新生血管性青光眼78例(3.1%)。
  • 5年免眼球摘除生存率内路切除组94.8% vs 内路引流组94.3% vs 对照组93.5%。
  • 5年放射性视网膜病变内路切除组30.5% vs 内路引流-玻璃体切除术组37.4% vs 对照组52.3%。
  • 5年新生血管性青光眼内路切除组11.6% vs 内路引流-玻璃体切除术组21.3% vs 对照组57.8%。

临床怎么用

  • 作者建议对不适合内路切除的患者行内路引流-玻璃体切除术,并认为内路切除是最有前景的辅助治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was performed to show long-term outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with the main focus on outcomes according to different adjuvant ab interno surgical procedures. DESIGN: Retrospective cohort study. METHODS: All patients treated with primary proton beam therapy for choroidal or ciliary body melanoma between June 1998 and June 2015 were included. RESULTS: A total of 2499 patients underwent primary proton beam therapy, with local tumor control and globe preservation rates of 95.9% and 94.8% after 5 years, respectively. A total of 110 (4.4%) patients required secondary enucleation. Unresponsive neovascular glaucoma was the leading cause of secondary enucleation in 78 of the 2499 patients (3.1%). The 5-year enucleation-free survival rate was 94.8% in the endoresection group, 94.3% in the endodrainage group, and 93.5% in the comparator group. The log-rank test showed P = .014 (comparator group vs endoresection group) and P = .06 (comparator group vs endodrainage-vitrectomy group). Patients treated with endoresection or endodrainage-vitrectomy developed less radiation retinopathy (30.5% and 37.4% after 5 years, P = .001 and P = .048 [Kaplan-Meier], respectively) and less neovascular glaucoma (11.6% and 21.3% after 5 years, P = .001 and P = .01 [Kaplan-Meier], respectively) compared with the comparator group (52.3% radiation retinopathy and 57.8% neovascular glaucoma after 5 years). CONCLUSION: This study suggests that in larger tumors the enucleation and neovascular glaucoma rates might be reduced by adjuvant surgical procedures. Although endoresection is the most promising adjuvant treatment option, the endodrainage-vitrectomy is recommended in patients who are ineligible for endoresection.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Seibel I, Riechardt AI, Heufelder J, et al. Adjuvant Ab Interno Tumor Treatment After Proton Beam Irradiation. Am J Ophthalmol. 2017. PMID: 28365241. doi:10.1016/j.ajo.2017.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。